Drug repurposing in oncology-patient and health systems opportunities

Francesco Bertolini, Vikas P. Sukhatme, Gauthier Bouche

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

In most countries, healthcare service budgets are not likely to support the current explosion in the cost of new oncology drugs. Repurposing the large arsenal of approved, non-anticancer drugs is an attractive strategy to offer more-effective options to patients with cancer, and has the substantial advantages of cheaper, faster and safer preclinical and clinical validation protocols. The potential benefits are so relevant that funding of academically and/or independently driven preclinical and clinical research programmes should be considered at both national and international levels. To date, successes in oncology drug repurposing have been limited, despite strong evidence supporting the use of many different drugs. A lack of financial incentives for drug developers and limited drug development experience within the non-profit sector are key reasons for this lack of success. We discuss these issues and offer solutions to finally seize this opportunity in the interest of patients and societies, globally.

Original languageEnglish
Pages (from-to)732-742
Number of pages11
JournalNature Reviews Clinical Oncology
Volume12
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Drug Repositioning
Health
Pharmaceutical Preparations
Explosions
Budgets
Clinical Protocols
Motivation
Delivery of Health Care
Costs and Cost Analysis
Research
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Drug repurposing in oncology-patient and health systems opportunities. / Bertolini, Francesco; Sukhatme, Vikas P.; Bouche, Gauthier.

In: Nature Reviews Clinical Oncology, Vol. 12, No. 12, 01.12.2015, p. 732-742.

Research output: Contribution to journalArticle

Bertolini, Francesco ; Sukhatme, Vikas P. ; Bouche, Gauthier. / Drug repurposing in oncology-patient and health systems opportunities. In: Nature Reviews Clinical Oncology. 2015 ; Vol. 12, No. 12. pp. 732-742.
@article{7f688397709c4570a0a5692c3bae34bc,
title = "Drug repurposing in oncology-patient and health systems opportunities",
abstract = "In most countries, healthcare service budgets are not likely to support the current explosion in the cost of new oncology drugs. Repurposing the large arsenal of approved, non-anticancer drugs is an attractive strategy to offer more-effective options to patients with cancer, and has the substantial advantages of cheaper, faster and safer preclinical and clinical validation protocols. The potential benefits are so relevant that funding of academically and/or independently driven preclinical and clinical research programmes should be considered at both national and international levels. To date, successes in oncology drug repurposing have been limited, despite strong evidence supporting the use of many different drugs. A lack of financial incentives for drug developers and limited drug development experience within the non-profit sector are key reasons for this lack of success. We discuss these issues and offer solutions to finally seize this opportunity in the interest of patients and societies, globally.",
author = "Francesco Bertolini and Sukhatme, {Vikas P.} and Gauthier Bouche",
year = "2015",
month = "12",
day = "1",
doi = "10.1038/nrclinonc.2015.169",
language = "English",
volume = "12",
pages = "732--742",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Drug repurposing in oncology-patient and health systems opportunities

AU - Bertolini, Francesco

AU - Sukhatme, Vikas P.

AU - Bouche, Gauthier

PY - 2015/12/1

Y1 - 2015/12/1

N2 - In most countries, healthcare service budgets are not likely to support the current explosion in the cost of new oncology drugs. Repurposing the large arsenal of approved, non-anticancer drugs is an attractive strategy to offer more-effective options to patients with cancer, and has the substantial advantages of cheaper, faster and safer preclinical and clinical validation protocols. The potential benefits are so relevant that funding of academically and/or independently driven preclinical and clinical research programmes should be considered at both national and international levels. To date, successes in oncology drug repurposing have been limited, despite strong evidence supporting the use of many different drugs. A lack of financial incentives for drug developers and limited drug development experience within the non-profit sector are key reasons for this lack of success. We discuss these issues and offer solutions to finally seize this opportunity in the interest of patients and societies, globally.

AB - In most countries, healthcare service budgets are not likely to support the current explosion in the cost of new oncology drugs. Repurposing the large arsenal of approved, non-anticancer drugs is an attractive strategy to offer more-effective options to patients with cancer, and has the substantial advantages of cheaper, faster and safer preclinical and clinical validation protocols. The potential benefits are so relevant that funding of academically and/or independently driven preclinical and clinical research programmes should be considered at both national and international levels. To date, successes in oncology drug repurposing have been limited, despite strong evidence supporting the use of many different drugs. A lack of financial incentives for drug developers and limited drug development experience within the non-profit sector are key reasons for this lack of success. We discuss these issues and offer solutions to finally seize this opportunity in the interest of patients and societies, globally.

UR - http://www.scopus.com/inward/record.url?scp=84948382896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948382896&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2015.169

DO - 10.1038/nrclinonc.2015.169

M3 - Article

C2 - 26483297

AN - SCOPUS:84948382896

VL - 12

SP - 732

EP - 742

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 12

ER -